Menu menu
  • Flux RSS
  • Twitter
  • Facebook
  • Google Plus
  • LinkedIn
  • YouTube

Press releases

Theraclion Announces First Patients Treated in (...)

2017

Theraclion (Alternext, FR0010120402 – ALTHE), a company specialized in leading-edge medical equipment for echotherapy, announce that the first patients were treated in the U.S. pivotal clinical trial to evaluate the safety and efficacy of Echopulse® echotherapy as a non-invasive treatment of breast fibroadenomas (BFAs).

  • Lire la suite
  • Articles similaires

Acticor Biotech Secures €1,5M new funding from (...)

2017

Acticor Biotech, a biotechnology company focused on the treatment of acute ischemic stroke, today announced that it has raised €1,5M from CapDecisif Management. Acticor Biotech had already secured €1,4M in the first closing, which brings the total amount invested to €2,9M.

  • Lire la suite
  • Articles similaires

METAglut1, a new diagnostic test

2017

Laboratoire Cerba and METAFORA biosystems are proud to announce the availability of the innovative test METAglut1 in routine biology to help diagnose the GLUT1 deficiency syndrome (GLUT1-DS)

  • Lire la suite
  • Articles similaires

Global Bioenergies finalizes acquisition of (...)

2017

Global Bioenergies (Alternext Paris : ALGBE) has finalized the acquisition of Syngip B.V. at the close of its extraordinary shareholders’ meeting today. Syngip B.V. is a start-up based in the Netherlands that specializes in converting third-generation resources into fuels and materials.

  • Lire la suite
  • Articles similaires

Butagaz becomes the first gas distributor in (...)

2017

Butagaz, a leading French brand distributing gas in bottles and tanks, continues its innovation drive to contribute to meeting France’s greenhouse gas emissions reduction target. The partnership with Global Bioenergies aims at incorporating batches of bio-isobutene produced at Global Bioenergies’ demo plant as early as 2017 and then by the first commercial bio-isobutene plant once built in (...)

  • Lire la suite
  • Articles similaires

CFI.co announces Pharnext as winner of the Best (...)

2017

Capital Finance International (CFI), a print journal and online resource reporting on business, economics, and finance and Pharnext SA (FR00111911287 - ALPHA), a French biopharmaceutical company developing an advanced portfolio of products in the field of neurodegenerative diseases, announced today that the CFI.co judges have conferred on Pharnext its Best Life-Sciences IPO France 2016 (...)

  • Lire la suite
  • Articles similaires

Insect Breeding Innovator Ynsect Raises $15.2m to (...)

2016

Ynsect – the global leader in the mass- scale breeding of insects for the animal feed markets – today announces that it has closed a $15.2m Series B round led by Future Positive Capital, Quadia SA and Bpifrance Ecotechnologies, with participation from existing investors Emertec, Demeter, Vis Vires New Protein Capital and Business Angels. This latest round brings the cumulative amount Ynsect has raised, from private and public sources, to $37m over the last three years – the largest-ever (...)

  • Lire la suite
  • Articles similaires

Genopole Young Biotech Award 2016 : Biostart wins (...)

2016

Having convinced the jury unanimously, the company Biostart was named laureate of the sixth edition of the Genopole Young Biotech Award at the awards ceremony held Tuesday 13 December at the Caisse d’Epargne headquarters in Paris. Two of the five finalists also took home special prizes : the project Spiris won the Industrial Potential prize and Unibiome the International Potential prize. Consult the Press Kit (...)

  • Lire la suite
  • Articles similaires

Jean-Marc Grognet succeeds Pierre Tambourin as (...)

2016

Jean-Marc Grognet was confirmed as the new chief executive of Genopole at the general assembly of the Groupement d’intéret public (GIP) Genopole. He will replace Pierre Tambourin, CEO since 1998.

  • Lire la suite
  • Articles similaires

Stroke company Acticor Biotech and Mediolanum (...)

2016

Acticor Biotech SAS and Mediolanum farmaceutici S.p.A., today announced that they have entered into a research collaboration agreement for Acticor’s project ACT-017, a humanized antibody Fragment (Fab). Under the terms of the agreement, Mediolanum will co-finance research and development of ACT-017, currently in preclinical development as a potential next generation antithrombotic treatment for acute ischemic (...)

  • Lire la suite
  • Articles similaires